Canaccord Genuity Downgrades MAP Pharmaceuticals (MAPP) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Deutsche Bank Downgrades MAP Pharmaceuticals (MAPP) to Hold; Doesn't Expect Other Bids
January 28, 2013 9:02 AM ESTDeutsche Bank downgraded MAP Pharmaceuticals (NASDAQ: MAPP) from Buy to Hold following takeover deal. The firm doesn't expect other bids.
For an analyst ratings summary and ratings history on MAP Pharmaceuticals click here. For... More
Leerink Swann Downgrades MAP Pharmaceuticals (MAPP) to Market Perform
January 24, 2013 6:54 AM ESTLeerink Swann downgraded MAP Pharmaceuticals (NASDAQ: MAPP) from Outperform to Market Perform with a price target of $25.00 (from $19.00) following yesterday's takeover deal.
"We believe MAPP's $25/share takeout valuation is fair and includes some of the technology value in MAPP's Tempo inhaler device... More
Allergan (AGN) Acquires MAP Pharmaceuticals (MAPP) for $958M
January 23, 2013 6:34 AM ESTAllergan, Inc. (NYSE: AGN) agreed to acquire MAP Pharmaceuticals, Inc. (NASDAQ: MAPP) for $25 per share, or approximately $958 million. The offer represents a 60% premium over MAPs closing stock price on the Nasdaq Stock Market of $15.58 on January 22, 2013.
The acquisition is expected to close late in the first quarter or in the second quarter of 2013.
In January 2011, Allergan entered into... More
